CLL (Chronic Lymphocytic Leukemia) Clinical Trials

6 recruitingLast updated: June 18, 2026

There are 6 actively recruiting cll (chronic lymphocytic leukemia) clinical trials across 2 countries. Studies span Phase 1, Phase 2, Not Applicable, Phase 3. Top locations include Duarte, California, United States, Bethesda, Maryland, United States, Columbus, Ohio, United States. Updated daily from ClinicalTrials.gov.


CLL (Chronic Lymphocytic Leukemia) Trials at a Glance

6 actively recruiting trials for cll (chronic lymphocytic leukemia) are listed on ClinicalTrialsFinder across 6 cities in 2 countries. The largest study group is Phase 1 with 2 trials, with the heaviest enrollment activity in Duarte, Bethesda, and Columbus. Lead sponsors running cll (chronic lymphocytic leukemia) studies include Center for International Blood and Marrow Transplant Research, Lomond Therapeutics Holdings, Inc., and National Heart, Lung, and Blood Institute (NHLBI).

Browse cll (chronic lymphocytic leukemia) trials by phase

Treatments under study

About CLL (Chronic Lymphocytic Leukemia) Clinical Trials

Looking for clinical trials for CLL (Chronic Lymphocytic Leukemia)? There are currently 6 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new CLL (Chronic Lymphocytic Leukemia) trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about CLL (Chronic Lymphocytic Leukemia) clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 16 of 6 trials

Recruiting

Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)

Small Lymphocytic LymphomaWaldenstrom MacroglobulinemiaLymphoplasmacytic Lymphoma+2 more
National Heart, Lung, and Blood Institute (NHLBI)1,000 enrolled1 locationNCT00923507
Recruiting
Phase 3

ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL

CLLCLL/SLLCLL (Chronic Lymphocytic Leukemia)+5 more
Newave Pharmaceutical Inc306 enrolled4 locationsNCT07342478
Recruiting
Not Applicable

CLL-IMPACT: A Clinical Nutrition Trial Investigating Immune and Metabolic Changes in Early-Stage CLL

CLL (Chronic Lymphocytic Leukemia)
Technical University of Munich50 enrolled1 locationNCT07487428
Recruiting
Phase 2

A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation

LymphomaMyelofibrosisAML (Acute Myelogenous Leukemia)+8 more
Center for International Blood and Marrow Transplant Research358 enrolled13 locationsNCT06859424
Recruiting
Phase 1Phase 2

A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies

Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaAcute Leukemia+8 more
Ossium Health, Inc.12 enrolled9 locationsNCT05589896
Recruiting
Phase 1

A Phase 1 Study of ZE50-0134 in Relapsed and Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Select Low-grad Lymphomas

CLL/SLLCLL (Chronic Lymphocytic Leukemia)SLL (Small Lymphocytic Lymphoma)
Lomond Therapeutics Holdings, Inc.66 enrolled4 locationsNCT06708897